Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Amiot

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Gastroenterologie Clinique Et Biologique|March 18, 2008
[Chronic intestinal pseudo-obstruction and anti-Hu syndrome: 13 years of follow-up without neoplasia]A Amiot, F Joly, B Messing, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2015
The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximabG Dumitrescu, A Amiot, P Seksik, et al.
Journal of Crohn'S & Colitis|December 31, 2014
Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's diseaseC Gagniere, L Beaugerie, B Pariente, et al.
The British Journal of Dermatology|November 16, 2018
Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case seriesS Gendreau, A Amiot, Y Le Baleur, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2014
Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational studyA Amiot, M Lévy, C Copie-Bergman, et al.
Alimentary Pharmacology & Therapeutics|October 14, 2017
Efficacy and safety of golimumab in Crohn's disease: a French national retrospective studyC Martineau, B Flourié, P Wils, et al.
Journal of Crohn'S & Colitis|February 26, 2022
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort StudyC Cottron, X Treton, R Altwegg, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter studyM Hupé, A Streichenberger, P Wils, et al.
Alimentary Pharmacology & Therapeutics|July 2, 2014
Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel diseaseM Seirafi, B de Vroey, A Amiot, et al.
Journal of Crohn'S & Colitis|March 13, 2020
Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort StudyT Severyns, J Kirchgesner, J Lambert, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Gastroenterologie Clinique Et Biologique|March 18, 2008
[Chronic intestinal pseudo-obstruction and anti-Hu syndrome: 13 years of follow-up without neoplasia]A Amiot, F Joly, B Messing, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2015
The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximabG Dumitrescu, A Amiot, P Seksik, et al.
Journal of Crohn'S & Colitis|December 31, 2014
Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's diseaseC Gagniere, L Beaugerie, B Pariente, et al.
The British Journal of Dermatology|November 16, 2018
Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case seriesS Gendreau, A Amiot, Y Le Baleur, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2014
Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational studyA Amiot, M Lévy, C Copie-Bergman, et al.
Alimentary Pharmacology & Therapeutics|October 14, 2017
Efficacy and safety of golimumab in Crohn's disease: a French national retrospective studyC Martineau, B Flourié, P Wils, et al.
Journal of Crohn'S & Colitis|February 26, 2022
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort StudyC Cottron, X Treton, R Altwegg, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter studyM Hupé, A Streichenberger, P Wils, et al.
Alimentary Pharmacology & Therapeutics|July 2, 2014
Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel diseaseM Seirafi, B de Vroey, A Amiot, et al.
Journal of Crohn'S & Colitis|March 13, 2020
Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort StudyT Severyns, J Kirchgesner, J Lambert, et al.
Pageof 3